Form 8-K - Current report:
SEC Accession No. 0001104659-23-099831
Filing Date
2023-09-12
Accepted
2023-09-12 06:05:19
Documents
51
Period of Report
2023-09-12
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2325915d1_8k.htm   iXBRL 8-K 24934
2 EXHIBIT 99.1 tm2325915d1_ex99-1.htm EX-99.1 57927
6 GRAPHIC tm2325915d1_ex99-1img001.jpg GRAPHIC 112176
7 GRAPHIC tm2325915d1_ex99-1img002.jpg GRAPHIC 338330
8 GRAPHIC tm2325915d1_ex99-1img003.jpg GRAPHIC 139652
9 GRAPHIC tm2325915d1_ex99-1img004.jpg GRAPHIC 91232
10 GRAPHIC tm2325915d1_ex99-1img005.jpg GRAPHIC 149557
11 GRAPHIC tm2325915d1_ex99-1img006.jpg GRAPHIC 138206
12 GRAPHIC tm2325915d1_ex99-1img007.jpg GRAPHIC 122413
13 GRAPHIC tm2325915d1_ex99-1img008.jpg GRAPHIC 185454
14 GRAPHIC tm2325915d1_ex99-1img009.jpg GRAPHIC 68769
15 GRAPHIC tm2325915d1_ex99-1img010.jpg GRAPHIC 117575
16 GRAPHIC tm2325915d1_ex99-1img011.jpg GRAPHIC 100773
17 GRAPHIC tm2325915d1_ex99-1img012.jpg GRAPHIC 78793
18 GRAPHIC tm2325915d1_ex99-1img013.jpg GRAPHIC 217037
19 GRAPHIC tm2325915d1_ex99-1img014.jpg GRAPHIC 159610
20 GRAPHIC tm2325915d1_ex99-1img015.jpg GRAPHIC 165188
21 GRAPHIC tm2325915d1_ex99-1img016.jpg GRAPHIC 110234
22 GRAPHIC tm2325915d1_ex99-1img017.jpg GRAPHIC 127847
23 GRAPHIC tm2325915d1_ex99-1img018.jpg GRAPHIC 133216
24 GRAPHIC tm2325915d1_ex99-1img019.jpg GRAPHIC 220228
25 GRAPHIC tm2325915d1_ex99-1img020.jpg GRAPHIC 204265
26 GRAPHIC tm2325915d1_ex99-1img021.jpg GRAPHIC 42702
27 GRAPHIC tm2325915d1_ex99-1img022.jpg GRAPHIC 157977
28 GRAPHIC tm2325915d1_ex99-1img023.jpg GRAPHIC 89952
29 GRAPHIC tm2325915d1_ex99-1img024.jpg GRAPHIC 127117
30 GRAPHIC tm2325915d1_ex99-1img025.jpg GRAPHIC 136132
31 GRAPHIC tm2325915d1_ex99-1img026.jpg GRAPHIC 110762
32 GRAPHIC tm2325915d1_ex99-1img027.jpg GRAPHIC 156885
33 GRAPHIC tm2325915d1_ex99-1img028.jpg GRAPHIC 134200
34 GRAPHIC tm2325915d1_ex99-1img029.jpg GRAPHIC 81973
35 GRAPHIC tm2325915d1_ex99-1img030.jpg GRAPHIC 209889
36 GRAPHIC tm2325915d1_ex99-1img031.jpg GRAPHIC 112306
37 GRAPHIC tm2325915d1_ex99-1img032.jpg GRAPHIC 59011
38 GRAPHIC tm2325915d1_ex99-1img033.jpg GRAPHIC 108739
39 GRAPHIC tm2325915d1_ex99-1img034.jpg GRAPHIC 138271
40 GRAPHIC tm2325915d1_ex99-1img035.jpg GRAPHIC 152073
41 GRAPHIC tm2325915d1_ex99-1img036.jpg GRAPHIC 150329
42 GRAPHIC tm2325915d1_ex99-1img037.jpg GRAPHIC 137033
43 GRAPHIC tm2325915d1_ex99-1img038.jpg GRAPHIC 171343
  Complete submission text file 0001104659-23-099831.txt   7516166

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tbph-20230912.xsd EX-101.SCH 3021
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tbph-20230912_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tbph-20230912_pre.xml EX-101.PRE 22363
45 EXTRACTED XBRL INSTANCE DOCUMENT tm2325915d1_8k_htm.xml XML 3331
Mailing Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104 650-808-6000
Theravance Biopharma, Inc. (Filer) CIK: 0001583107 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36033 | Film No.: 231248946
SIC: 2834 Pharmaceutical Preparations